EKSO (Ekso Bionics Holdings) Beneish M-Score: -3.82 (As of Jun. 25, 2026)


EKSO Ekso Bionics Holdings Inc EKSO
32 GF Score
Price $11.65
GF Value $4.31
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Ekso Bionics Holdings Beneish M-Score?

Ekso Bionics Holdings EKSO -0.42% 32 Beneish M-Score is -3.82 as of Jun. 25, 2026. GuruFocus rates EKSO with a GF Score™ of 32/100 and a GF Value™ of $4.31 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 766 Medical Devices & Instruments companies, Ekso Bionics Holdings ranks better than 92.3% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.82 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Ekso Bionics Holdings's Beneish M-Score or its related term are showing as below:

EKSO' s Beneish M-Score Range Over the Past 10 Years
Min: -4.86   Med: -2.85   Max: 18.59
Current: -3.82

During the past 13 years, the highest Beneish M-Score of Ekso Bionics Holdings was 18.59. The lowest was -4.86. And the median was -2.85.


Ekso Bionics Holdings Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Ekso Bionics Holdings's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ekso Bionics Holdings Beneish M-Score Chart

Ekso Bionics Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.58 14.44 -2.78 -2.36 -2.89

Ekso Bionics Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.88 -3.49 -3.12 -2.89 -3.82

EKSO vs POCI, HBIO, NEPH: Beneish M-Score Comparison

For the Medical Instruments & Supplies subindustry, Ekso Bionics Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ekso Bionics Holdings Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Ekso Bionics Holdings's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Ekso Bionics Holdings's Beneish M-Score falls into.


EKSO
32GF Score
Ekso Bionics Holdings Inc EKSO
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ekso Bionics Holdings Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Ekso Bionics Holdings for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0659+0.528 * 1.01+0.404 * 1.1307+0.892 * 0.6592+0.115 * 0.8009
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.7691+4.679 * -0.206986-0.327 * 1.0815
=-3.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was $4.54 Mil.
Revenue was 2.141 + 3.14 + 4.227 + 2.057 = $11.57 Mil.
Gross Profit was 1.074 + 1.671 + 2.549 + 0.819 = $6.11 Mil.
Total Current Assets was $14.05 Mil.
Total Assets was $19.67 Mil.
Property, Plant and Equipment(Net PPE) was $1.46 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.65 Mil.
Selling, General, & Admin. Expense(SGA) was $18.99 Mil.
Total Current Liabilities was $9.09 Mil.
Long-Term Debt & Capital Lease Obligation was $0.64 Mil.
Net Income was -6.885 + -4.674 + -1.421 + -2.709 = $-15.69 Mil.
Non Operating Income was -0.979 + -0.01 + -0.001 + 1.331 = $0.34 Mil.
Cash Flow from Operations was -2.123 + -4.331 + -2.061 + -3.444 = $-11.96 Mil.
Total Receivables was $6.46 Mil.
Revenue was 3.375 + 5.09 + 4.129 + 4.95 = $17.54 Mil.
Gross Profit was 1.806 + 2.714 + 2.209 + 2.637 = $9.37 Mil.
Total Current Assets was $20.07 Mil.
Total Assets was $27.31 Mil.
Property, Plant and Equipment(Net PPE) was $2.14 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.58 Mil.
Selling, General, & Admin. Expense(SGA) was $16.28 Mil.
Total Current Liabilities was $8.55 Mil.
Long-Term Debt & Capital Lease Obligation was $3.94 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(4.537 / 11.565) / (6.457 / 17.544)
=0.392304 / 0.368046
=1.0659

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(9.366 / 17.544) / (6.113 / 11.565)
=0.533858 / 0.528578
=1.01

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (14.053 + 1.458) / 19.668) / (1 - (20.068 + 2.137) / 27.31)
=0.211359 / 0.186928
=1.1307

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=11.565 / 17.544
=0.6592

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.58 / (1.58 + 2.137)) / (1.649 / (1.649 + 1.458))
=0.425074 / 0.530737
=0.8009

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(18.99 / 11.565) / (16.284 / 17.544)
=1.642023 / 0.928181
=1.7691

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.641 + 9.091) / 19.668) / ((3.942 + 8.553) / 27.31)
=0.494814 / 0.457525
=1.0815

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-15.689 - 0.341 - -11.959) / 19.668
=-0.206986

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Ekso Bionics Holdings has a M-score of -3.82 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -3.82 mean?
Ekso Bionics Holdings (EKSO) has a Beneish M-Score of -3.82 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Ekso Bionics Holdings and its competitors. According to the industry distribution chart, Ekso Bionics Holdings ranks #59 out of 766 companies in the Medical Devices & Instruments industry, placing it in the top 7.7%.
Is Ekso Bionics Holdings' Beneish M-Score too high?
Ekso Bionics Holdings' current Beneish M-Score is -3.82. Based on the distribution chart, Ekso Bionics Holdings ranks #59 out of 766 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Ekso Bionics Holdings has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ekso Bionics Holdings' Beneish M-Score compare to POCI and HBIO?
According to the Medical Devices & Instruments industry distribution chart, Ekso Bionics Holdings ranks #59 out of 766 companies for Beneish M-Score. This places Ekso Bionics Holdings in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Ekso Bionics Holdings and its competitors. Ekso Bionics Holdings's current Beneish M-Score is -3.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ekso Bionics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Ekso Bionics Holdings (EKSO) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.31, compared to a current price of $11.65 — trading 170.3% above its estimated fair value. The current Beneish M-Score is -3.82. Ekso Bionics Holdings' overall GF Score™ is 32/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Ekso Bionics Holdings (EKSO), the current Beneish M-Score is -3.82 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ekso Bionics Holdings (EKSO) Overvalued in 2026?

Based on GuruFocus' analysis, Ekso Bionics Holdings stock appears to be overvalued. The current stock price of $11.65 is trading 170.3% above its estimated GF Value™ of $4.31. GuruFocus considers Ekso Bionics Holdings to be Significantly Overvalued.

Key valuation signals for EKSO:

  • Beneish M-Score: -3.82
  • GF Value™: $4.31 vs. price of $11.65 (170.3% above fair value)
  • GF Score™: 32/100 with 10 warning signs

No single metric tells the full story. See the EKSO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ekso Bionics Holdings Business Description

Address 101 Glacier Point, Suite A, San Rafael, CA, USA, 94901
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
32GF Score

Get the complete analysis for EKSO

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.65
Price
$4.31
GF Value